← Back

Jiangsu Beiren Robot System Co Ltd

Jiangsu Beiren Robot System Co., Ltd. researches, develops, designs, produces, assembles, and sells production lines, primarily in China. Its offerings include embodied intelligent welding robots, new energy vehicle welding production lines, flexible automated welding and assembly production lines, intelligent welding equipment, laser processing equipment, polishing and grinding equipment, production management information systems, and digital workshops. It also supplies chassis, battery trays, body-in-white production lines, and standard products, serving the automotive, aerospace, shipbuilding, heavy industry, and other sectors. Founded in 2010, the company is based in Suzhou, China.

Price · split & dividend adjusted
News & notes moving 688218.CG
China
688218.CG

Jiangsu Beiren Releases 2026 Interim Report with Net Profit of 15.8213 Million Yuan

Jiangsu Beiren released its 2026 interim report on August 22, 2026. The company's total operating revenue was 250 million yuan, net profit attributable to the parent company was 15.8213 million yuan, and net cash inflow from operating activities was 62.154 million yuan. The company's latest asset-liability ratio was 56.75%, up 3.94 percentage points from the same period last year. The latest gross margin was 27.27%, the latest return on equity was 1.79%, and diluted earnings per share was 0.14 yuan. The company's latest total asset turnover was 0.13 times, and the latest inventory turnover was 0.19 times, down 17.71% from the same period last year. The company had 8,410 shareholders, and the top ten shareholders held 44.6589 million shares, accounting for 38.34% of the total share capital.
688218.CG · Capital · Neutral Company released its 2026 interim report with net profit of 15.8213 million yuan, but no comparative figures or market expectations are provided to judge positive or negative impact.
Read original ↗
Jiemian·43dRead more →
688218.CG▲2

Over 20 Shanghai-Listed Companies Release Positive Announcements on Buybacks, Earnings, and Interim Dividends

This evening, more than 20 companies listed on the Shanghai Stock Exchange released a wave of positive signals, covering share buybacks and stake increases, strong operating results, and interim dividend returns. Four companies announced new buyback plans, with a combined proposed buyback cap of 320 million yuan. Three companies announced new stake increase plans, with a combined proposed increase cap of 166 million yuan. Another six companies disclosed progress updates on buybacks. On the operational front, Pingdingshan Tianan Coal Mining reported a 25.58 percent year-on-year rise in commercial coal sales revenue in the first half. Sichuan Biokin Pharmaceutical received clinical trial approval for its injectable drug BL-B01D1 for subcutaneous administration. Farsoon Technologies posted an 87 percent year-on-year increase in net profit attributable to the parent company in the first half. Jiangsu Beiren Robot System projected a net profit attributable to the parent company of 15.8213 million yuan for the first half of 2026, swinging to a profit. Acter Group reported a 205 percent year-on-year jump in net profit for the first half. In terms of shareholder returns, Eastroc Beverage plans to distribute approximately 2.2 billion yuan in cash dividends for the half year. OPT Machine Vision Tech disclosed that its actual controller has proposed an interim dividend arrangement. And the controlling shareholder of Lead Intelligent Equipment voluntarily committed not to reduce its stake in the company within the next 12 months.
601666.CG · Demand · Positive Reported 25.58% YoY rise in commercial coal sales revenue in H1
605499.CG · Capital · Positive Plans to distribute ~2.2 billion yuan in cash dividends for H1
688218.CG · Capital · Positive Projected net profit of 15.8213 million yuan for H1 2026, swinging to profit
688433.CG · Capital · Positive Posted 87% YoY increase in net profit attributable to parent in H1
688506.CG · Technology · Positive Received clinical trial approval for injectable drug BL-B01D1 for subcutaneous administration
688686.CG · Capital · Positive Actual controller proposed interim dividend arrangement, a positive capital return signal.
Read original ↗